Oxygen (DrugBank: Oxygen)
18 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 2 |
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
| 19 | ライソゾーム病 | 1 |
| 46 | 悪性関節リウマチ | 1 |
| 49 | 全身性エリテマトーデス | 1 |
| 70 | 広範脊柱管狭窄症 | 2 |
| 84 | サルコイドーシス | 1 |
| 85 | 特発性間質性肺炎 | 12 |
| 86 | 肺動脈性肺高血圧症 | 6 |
| 88 | 慢性血栓塞栓性肺高血圧症 | 6 |
| 90 | 網膜色素変性症 | 2 |
| 96 | クローン病 | 2 |
| 97 | 潰瘍性大腸炎 | 2 |
| 193 | プラダー・ウィリ症候群 | 1 |
| 226 | 間質性膀胱炎（ハンナ型） | 3 |
| 294 | 先天性横隔膜ヘルニア | 1 |
| 299 | 嚢胞性線維症 | 8 |
| 330 | 先天性気管狭窄症／先天性声門下狭窄症［先天性気管狭窄症（~2018.3）］ | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03229174 (ClinicalTrials.gov) | August 23, 2018 | 21/4/2017 | Brain Perfusion & Oxygenation in Parkinson's Disease With NOH | Evaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus Placebo | Parkinson Disease;Neurogenic Orthostatic Hypotension | Drug: Droxidopa;Drug: Placebo | William Ondo, MD | Lundbeck LLC | Recruiting | 18 Years | 85 Years | All | 28 | Phase 4 | United States |
| 2 | NCT03407378 (ClinicalTrials.gov) | June 26, 2018 | 15/1/2018 | A Study to Investigate a New Treatment in Patients With Parkinson's Disease | A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease | Parkinson Disease | Drug: IPT803;Genetic: Optional pharmacogenetic assessment;Other: Questionnaires;Other: Optional Blood-Oxygen-level Dependent functionalMRI;Other: Motor Assessments before taking regular PD treatment;Other: Motor Assessments on regular PD treatment | Tools4Patient | NULL | Completed | 35 Years | N/A | All | 110 | Phase 1;Phase 2 | United States;Belgium;France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03983720 (ClinicalTrials.gov) | January 21, 2020 | 7/6/2019 | Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis? | Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis? | Sclerosis, Multiple | Other: Evaluation of degree chronic fatigue.;Other: Questionnaires;Biological: Blood sample;Other: Cardiopulmonary evaluation;Device: Capacity of muscular oxygen extraction;Device: Sleep assessment;Device: Metabolic fatigue;Other: Neuromuscular evaluation | Centre Hospitalier Universitaire de Saint Etienne | NULL | Recruiting | 18 Years | 70 Years | All | 60 | Phase 2 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02023086 (ClinicalTrials.gov) | August 2014 | 10/12/2013 | Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients | Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Relation With Visual Field Loss in Fabry Patients | Fabry Disease | Procedure: Contrast sensitivity measurement;Procedure: Slit Lamp assessment and intra-ocular pressure measurement;Procedure: Visual field testing;Procedure: Oxygen flow at the optic nerve head measurement;Drug: Tropicamide;Device: OSOME | Université de Montréal | Genzyme, a Sanofi Company | Completed | 18 Years | N/A | All | 8 | N/A | Canada |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02984943 (ClinicalTrials.gov) | January 19, 2017 | 15/11/2016 | The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis | The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis: A Pilot Study | RheumatoId Arthritis | Device: Hyperbaric Oxygen | David Grant U.S. Air Force Medical Center | NULL | Completed | 18 Years | N/A | All | 14 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-IOR-17012802 | 2017-09-26 | 2017-09-26 | Synergy effects and health regulation effect of oxygen-ozone therapy on systemic lupus erythematosus (SLE) | Synergy effects and health regulation effect of oxygen-ozone therapy on systemic lupus erythematosus (SLE) | systemic lupus erythematosus (SLE) | the Controled Group:basic oral therapy;the Treated Group:basic oral therapy + Autologous blood transfusion with oxygen-ozone + acupoint injection with oxygen-ozone on ST 36; | Guangdong Provincial Hospital of Chinese Medicine | NULL | Recruiting | 18 | 65 | Both | the Controled Group:30;the Treated Group:30; | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03088306 (ClinicalTrials.gov) | July 1, 2017 | 22/2/2017 | Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients | Comparative Effectiveness of Multi-modal Pain Management Versus Standard Intra- and Post-operative Analgesia: Randomized Controlled Clinical Trial to Reduce Post-operative Pain and Opioid Use Among Patients Undergoing Lumbar Spine Surgery | Lumbar Spinal Stenosis;Lumbar Spinal Instability;Lumbar Spine Degeneration | Drug: Standard analgesia use [Oxygen];Drug: Standard analgesia use [Hydromorphone];Drug: Standard analgesia use [Volatile Anesthesia];Drug: Standard analgesia use [Fentanyl];Drug: Multi-modal pain management [Acetaminophen + Gabapentin];Drug: Multi-modal pain management [Fentanyl];Drug: Multi-modal pain management [Intravenous Ketamine];Drug: Multi-modal pain management [Valium + Gabapentin] | Johns Hopkins University | North American Spine Society | Completed | 18 Years | 100 Years | All | 49 | Early Phase 1 | United States |
| 2 | NCT02625194 (ClinicalTrials.gov) | January 1, 2016 | 25/11/2015 | The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation | The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation | Lumbar Spinal Stenosis | Drug: Oxygen | Yonsei University | NULL | Completed | 20 Years | 60 Years | All | 36 | N/A | Korea, Republic of |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02246023 (ClinicalTrials.gov) | January 2015 | 15/9/2014 | Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy | Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial. | Lung Cancer;Sarcoidosis;Interstitial Pneumonia | Device: Flexible bronchoscopy in moderate sedation;Device: Oxygen saturation;Device: Blood pressure;Device: Propofol dosage;Device: Recovery time after bronchoscopy | Daniel Franzen | B. Braun Melsungen AG | Completed | 18 Years | 85 Years | Both | 78 | Phase 4 | Switzerland |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04564664 (ClinicalTrials.gov) | March 1, 2019 | 14/9/2020 | High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis | High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis: a Crossover Clinical Trial | Idiopathic Pulmonary Fibrosis | Drug: Oxygen | Parc de Salut Mar | Hospitales Universitarios Virgen del Rocío | Recruiting | 18 Years | 85 Years | All | 10 | N/A | Spain |
| 2 | NCT03688334 (ClinicalTrials.gov) | June 1, 2018 | 20/9/2018 | Acute Effects of Oxygen Supplementation Among IPF Patients | Acute Effects of Oxygen Supplementation During Exercise Among Patients With Idiopathic Pulmonary Fibrosis Without Resting Hypoxemia | Idiopathic Pulmonary Fibrosis | Drug: Oxygen 40 %;Drug: Medical air (sham O2) | George Papanicolaou Hospital | NULL | Unknown status | 18 Years | 80 Years | All | 15 | N/A | Greece |
| 3 | EUCTR2017-001276-27-GB (EUCTR) | 21/08/2017 | 03/05/2017 | A study to determine if GBT440 can increase the level of oxygen in the blood of people with Idiopathic Pulmonary Fibrosis (IPF) who need to use supplemental oxygen when resting. | A Phase II open label study to evaluate the effect of GBT440 on hypoxemia in subjects with Idiopathic Pulmonary Fibrosis (IPF) who are using supplemental oxygen at rest (ZEPHYR) - ZEPHYR | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Global Blood Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | 32 | Phase 2 | United States;United Kingdom | |||
| 4 | NCT03050255 (ClinicalTrials.gov) | November 2016 | 25/11/2016 | Short-term Effects of Supplemental Oxygen in Patients With IPF | Short-term Effects of Supplemental Oxygen During Walking in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Other: Medical air;Other: Oxygen (2Liter/min);Other: Oxygen (4Liter/min) | Schön Klinik Berchtesgadener Land | Linde AG | Completed | N/A | N/A | All | 53 | N/A | Germany |
| 5 | NCT02989168 (ClinicalTrials.gov) | November 2016 | 28/11/2016 | Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest | A Phase II Open Label Study to Evaluate the Effect of GBT440 on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Who Are Using Supplemental Oxygen at Rest (ZEPHYR) | Idiopathic Pulmonary Fibrosis;Hypoxemia | Drug: GBT440 | Global Blood Therapeutics | NULL | Terminated | 45 Years | 85 Years | All | 14 | Phase 2 | United States;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02551068 (ClinicalTrials.gov) | December 2015 | 1/9/2015 | High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib | High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib: The HOPE-IPF Study | Idiopathic Pulmonary Fibrosis | Other: 60% Oxygen;Other: Standard of Care | University of British Columbia | Boehringer Ingelheim | Recruiting | 19 Years | N/A | All | 88 | N/A | Canada |
| 7 | NCT02267655 (ClinicalTrials.gov) | May 2015 | 7/10/2014 | 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF | An Exploratory, 3-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects With WHO Group 3 PH Associated With Idiopathic Pulmonary Fibrosis (IPF) on LTOT (Part 2 and Part 3) | Pulmonary Hypertension;Chronic Obstructive Pulmonary Disease;Idiopathic Pulmonary Fibrosis | Drug: inhaled Nitric Oxide - 30 mcg/kg IBW/hr;Drug: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr;Drug: inhaled nitric oxide 75 mcg/kg IBW/hr | Bellerophon | NULL | Completed | 40 Years | 80 Years | All | 8 | Phase 1 | Belgium |
| 8 | EUCTR2014-003423-21-BE (EUCTR) | 29/09/2014 | 29/08/2014 | Evaluation of impact of inhaled nitric oxide on pulmonary vessel blood volume measured by high resolution computed tomography (HRCT) in subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in subjects with WHO Group 3 Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF) on Long-Term Oxygen Therapy (LTOT) (Part 2). | An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects with WHO Group 3 PH associated with Idiopathic pulmonary fibrosis (IPF) on LTOT (Part 2). | Part 1: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) Part 2: Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 18.1;Level: LLT;Classification code 10010952;Term: COPD;Classification code 10009033;Term: Chronic obstructive pulmonary disease;Classification code 10037400;Term: Pulmonary hypertension;Level: HLT;Classification code 10037401;Term: Pulmonary hypertensions;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: INOmax 400ppm mol/mol inhalation gas Product Name: INO INN or Proposed INN: NITRIC OXIDE | Bellerophon Pulse Technologies LLC | NULL | Not Recruiting | Female: yes Male: yes | Phase 1;Phase 2 | Belgium | |||
| 9 | NCT02248064 (ClinicalTrials.gov) | July 2014 | 12/9/2014 | Auto-titrating Oxygen in Chronic Respiratory Failure | The Assessment of Intelligent Oxygen Therapy (iO2t) in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF) | Chronic Obstructive Pulmonary Disease;Idiopathic Pulmonary Fibrosis | Device: Auto-titrating oxygen system | Imperial College London | NULL | Completed | 18 Years | N/A | Both | 26 | N/A | United Kingdom |
| 10 | NCT01214187 (ClinicalTrials.gov) | July 2011 | 30/9/2010 | Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis | Phase II Study of Inhaled CO for the Treatment of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: inhaled carbon monoxide;Other: Oxygen | Brigham and Women's Hospital | National Heart, Lung, and Blood Institute (NHLBI);University of California, San Francisco;University of Chicago;University of Illinois at Chicago;University of Michigan;Columbia University;Tulane University;University of Washington | Completed | 18 Years | 85 Years | All | 58 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | JPRN-UMIN000005098 | 2011/02/01 | 18/02/2011 | A randomized trial of ambulatory oxygen in patients with idiopathic pulmonary fibrosis and desaturation but without resting hypoxemia | idiopathic pulmonary fibrosis | ambulatory oxygen ambulatory air | Department of Respiratory Medicine and Allergology, Kinki University School of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan | |
| 12 | JPRN-UMIN000025256 | 2009/01/01 | 13/12/2016 | Benefits of supplemental oxygen on exercise capacity and dyspnea in IPF patients | idiopathic pulmonary fibrosis | oxygen gas air gas | Tosei General Hospital | NULL | Complete: follow-up complete | Not applicable | 75years-old | Male and Female | 106 | Not applicable | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04207593 (ClinicalTrials.gov) | April 1, 2019 | 17/12/2019 | The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia | Prospective, Randomized, Controlled Trial of the Effect of Long-term Oxygen Therapy on 6-minute Walking Distance, Clinical Parameters and Hemodynamics in Patients With PAH and CTEPH | Oxygen Deficiency;Pulmonary Arterial Hypertension;CTEPH | Drug: Oxygen | Heidelberg University | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 2 | Germany |
| 2 | EUCTR2018-001387-39-DE (EUCTR) | 15/03/2019 | 30/01/2019 | The effect of oxygen therapy in patients with pulmonary Hypertension. | A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) - SOPHA | pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Thoraxklinik-Heidelberg gGmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | Germany | |||
| 3 | NCT03683082 (ClinicalTrials.gov) | June 5, 2018 | 20/9/2018 | Oxygen Treatment and Pulmonary Arterial Hypertension | Acute Effects of Oxygen Supplementation Among Pulmonary Arterial Hypertension Patients | Pulmonary Arterial Hypertension | Drug: Oxygen supplementation;Drug: Sham O2 (medical air) | George Papanicolaou Hospital | NULL | Unknown status | 18 Years | 80 Years | All | 10 | N/A | Greece |
| 4 | NCT02661802 (ClinicalTrials.gov) | January 2012 | 20/1/2016 | Effects Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome | Acute Effects of 40% Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome | Eisenmenger Complex;Hypertension, Pulmonary | Other: Oxygen Supplementation | Federal University of São Paulo | NULL | Completed | 18 Years | 60 Years | Both | 30 | N/A | NULL |
| 5 | NCT00626028 (ClinicalTrials.gov) | September 2004 | 20/2/2008 | Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing | Comparison of Supplemental Oxygen and Nitric Oxide for Inhalation Plus Oxygen in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator Testing | Idiopathic Pulmonary Arterial Hypertension;Cardiomyopathy | Drug: Nitric Oxide for inhalation;Drug: Oxygen;Drug: Nitric Oxide plus Oxygen | Mallinckrodt | NULL | Completed | N/A | 18 Years | All | 136 | Phase 3 | United States;France;Netherlands;Spain;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00317486 (ClinicalTrials.gov) | September 2003 | 21/4/2006 | Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology | A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology | Pulmonary Arterial Hypertension Related to Eisenmenger Physiology | Drug: bosentan | Actelion | NULL | Completed | 12 Years | N/A | Both | 54 | Phase 4 | United States;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04207593 (ClinicalTrials.gov) | April 1, 2019 | 17/12/2019 | The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia | Prospective, Randomized, Controlled Trial of the Effect of Long-term Oxygen Therapy on 6-minute Walking Distance, Clinical Parameters and Hemodynamics in Patients With PAH and CTEPH | Oxygen Deficiency;Pulmonary Arterial Hypertension;CTEPH | Drug: Oxygen | Heidelberg University | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 2 | Germany |
| 2 | EUCTR2018-001387-39-DE (EUCTR) | 15/03/2019 | 30/01/2019 | The effect of oxygen therapy in patients with pulmonary Hypertension. | A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) - SOPHA | pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Thoraxklinik-Heidelberg gGmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | Germany | |||
| 3 | NCT02558582 (ClinicalTrials.gov) | September 2015 | 14/9/2015 | Effect of Exercise Training in Patients With Pulmonary Hypertension | Effect of Exercise Training in Arterial and Chronic Thromboembolic Pulmonary Hypertension in Switzerland and Standardization With European Countries | Hypertension, Pulmonary | Behavioral: respiratory and exercise therapy;Behavioral: respiratory and exercise therapy with supplemental oxygen | University of Zurich | NULL | Recruiting | 18 Years | N/A | All | 32 | N/A | Switzerland |
| 4 | JPRN-UMIN000026882 | 2015/04/01 | 10/04/2017 | Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension. | Effect of oxygen administration on pulmonary vascular resistance and cardiac index in patients with chronic thromboembolic pulmonary hypertension. - Effect of oxygen administration on PVR and CI in CTEPH. | chronic thromboembolic pulmonary hypertension. | Oxygen administration | Department of Cardiology, Hospital Organization Okayama Medical Center | NULL | Complete: follow-up continuing | 20years-old | Not applicable | Male and Female | 100 | Not applicable | Japan |
| 5 | NCT01884012 (ClinicalTrials.gov) | May 2013 | 13/5/2013 | Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension | Procedure: long term oxygen therapy | University of Zurich | NULL | Completed | 16 Years | 85 Years | All | 30 | Phase 3 | Switzerland | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT01748474 (ClinicalTrials.gov) | December 2012 | 4/10/2012 | Effect of Short-term Oxygen During CPET in Pulmonary Hypertension | Effect of Short-term Oxygen Therapy on Cardiopulmonary Exercise Capacity in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension;Chronic Cardiorespiratory Disease | Procedure: Supplemental oxygen via a mask | University of Zurich | NULL | Completed | 20 Years | 80 Years | Both | 20 | Phase 2 | Switzerland |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02465749 (ClinicalTrials.gov) | May 2015 | 22/5/2015 | Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa | Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Continuous oxygen;Device: blue light-absorbing sunglasses;Drug: Compound thrombosis capsule sig: 1.5g/tid;Drug: Ginkgo biloba pills sig: 300mg/tid;Drug: Vitamin B sig: 10mg/tid;Drug: Vitamin AD sig: 1 tablet/tid | Sun Yat-sen University | Zhujiang Hospital;Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;Guangzhou Jeeyor Medical Research Co.,Ltd. | Not yet recruiting | 18 Years | 60 Years | Both | 404 | Phase 0 | China |
| 2 | NCT00461435 (ClinicalTrials.gov) | January 2004 | 17/4/2007 | Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa | Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa | Retinitis Pigmentosa | Procedure: hyperbaric oxygen therapy | Azienda Policlinico Umberto I | NULL | Completed | 20 Years | 70 Years | Both | N/A | Italy |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800019958 | 2018-12-16 | 2018-12-09 | Combining infliximab with Hyperbaric Oxygen Therapy in Patients With Perianal Crohn's Disease | Combining infliximab with Hyperbaric Oxygen Therapy in Patients With Perianal Crohn's Disease | Crohn's disease | Case series:Combining infliximab treatmentwith Hyperbaric Oxygen Therapy; | Daping Hospital, Army Medical University (Third Military Medical University) | NULL | Recruiting | 18 | 65 | Both | Case series:60; | China | |
| 2 | NCT01828190 (ClinicalTrials.gov) | March 2013 | 8/4/2013 | The Influence of Hyperbaric Oxygen in Patients With Perianal Crohn's Disease Already Treated With TNF Alpha Blockers Treated With TNF Alpha Blockers | Prospective Open-label Study of the Efficacy of the Addition of Hyperbaric Oxygen to the Treatment of Patients With Perianal Fistulas Already Treated With TNF Alpha Blockers | Crohn's Disease;Perianal Fistulas | Other: Hyperbaric oxygen | Assaf-Harofeh Medical Center | NULL | Recruiting | 18 Years | 70 Years | Both | 50 | N/A | Israel |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03494764 (ClinicalTrials.gov) | September 7, 2017 | 4/4/2018 | Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares | Hyperbaric Oxygen Therapy for Moderate to Severe Ulcerative Colitis Flares: A Multi-Center Randomized Trial | Colitis, Ulcerative | Other: Hyperbaric Oxygen Therapy | Dartmouth-Hitchcock Medical Center | Foundation for Clinical Research in IBD;The Eli and Edythe Broad Foundation;University of California, San Diego;Mayo Clinic;University of Pittsburgh Medical Center;Virginia Mason Memorial Hospital;University of Texas Southwestern Medical Center;University of Maryland, College Park;NYU Langone Health | Active, not recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States |
| 2 | NCT02144350 (ClinicalTrials.gov) | August 2013 | 13/5/2014 | Hyperbaric Oxygen for Ulcerative Colitis | Hyperbaric Oxygen Therapy for Moderate to Severe Ulcerative Colitis Flares: A Multi-center Randomized Double Blind Sham Controlled Trial | Ulcerative Colitis | Procedure: Hyperbaric oxygen;Procedure: Sham Hyperbaric Air | Dartmouth-Hitchcock Medical Center | Mayo Clinic;University of Pittsburgh | Terminated | 18 Years | N/A | All | 18 | Phase 2;Phase 3 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03031626 (ClinicalTrials.gov) | September 1, 2016 | 20/1/2017 | Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome | Comparison of Therapeutic Oxygen Versus Medical Air for the Treatment of Central Sleep Apnea in Infants and Children With Prader Willi Syndrome: A Proof of Concept Study | Sleep Apnea, Central;Prader-Willi Syndrome | Biological: Medical Air vs Oxygen | The Hospital for Sick Children | NULL | Recruiting | N/A | 2 Years | All | 10 | Phase 4 | Canada |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03143920 (ClinicalTrials.gov) | November 1, 2017 | 2/5/2017 | Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder | Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder: A Feasibility Trial | Chronic Interstitial Cystitis;Painful Bladder Syndrome;Recurrent Urinary Tract Infection | Combination Product: Hyperbaric Oxygen Therapy- | University of California, San Diego | NULL | Recruiting | 35 Years | 70 Years | Female | 40 | Early Phase 1 | United States |
| 2 | NCT03693001 (ClinicalTrials.gov) | June 1, 2016 | 28/9/2018 | HBOT for Patients With IC/FM (Interstitial Cystitis/Fibromyalgia) | Clinical and Morphological Effects of Hyperbaric Oxygen Therapy in Patients With Interstitial Cystitis Associated With Fibromyalgia | Fibromyalgia;Interstitial Cystitis | Device: Intermittent Exposure to Oxygen via Oro-Nasal Mask | University of South Florida | University of Padova | Completed | 18 Years | N/A | All | 12 | N/A | NULL |
| 3 | NCT01069263 (ClinicalTrials.gov) | February 2010 | 10/1/2010 | Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis | Comparison Between Hyperbaric Oxygen Therapy (HBOT) and Intravesical Dimethyl Sulfoxide (DMSO) Instillation for the Treatment of Interstitial Cystitis - a Prospective, Randomized Cross-over Trial | Interstitial Cystitis | Other: Hyperbaric Oxygen Therapy;Drug: DMSO | Assaf-Harofeh Medical Center | NULL | Recruiting | 18 Years | 85 Years | Both | 60 | N/A | Israel |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03787160 (ClinicalTrials.gov) | March 22, 2018 | 10/7/2018 | Microbiome and Volatile Organic Compounds in Patients With CDH | Determining the Effect of Probiotics on Microbiome and Volatile Organic Compounds in Patients After Surgical Repair of Congenital Diaphragmatic Hernia | Congenital Diaphragmatic Hernia | Diagnostic Test: initial VOC;Diagnostic Test: initial fecal microbiome;Diagnostic Test: initial pulmonary microbiome;Diagnostic Test: Maximum oxygen uptake;Diagnostic Test: Functional residual capacity;Dietary Supplement: Probiotic treatment;Diagnostic Test: VOC probiotic;Diagnostic Test: Fecal microbiome probiotic;Diagnostic Test: Pulmonary microbiome probiotic | Medical University of Graz | University of Rostock | Completed | 6 Years | 16 Years | All | 18 | N/A | Austria |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03965832 (ClinicalTrials.gov) | May 24, 2019 | 24/5/2019 | HFNT During Exercise in CF | A Pilot Study to Evaluate the Feasibility of Using High-flow Nasal Therapy During Exercise in Patients With Cystic Fibrosis and Severe Lung Disease | Cystic Fibrosis | Device: HFNT during exercise;Device: Standard oxygen therapy/RA | The Leeds Teaching Hospitals NHS Trust | NULL | Recruiting | 18 Years | N/A | All | 20 | N/A | United Kingdom |
| 2 | NCT03902236 (ClinicalTrials.gov) | March 1, 2019 | 1/4/2019 | Reaction Time and Postural Control in Individuals With Cystic Fibrosis and Bronchiectasis | Evaluation of Reaction Time and Postural Control in Individuals With Cystic Fibrosis and Bronchiectasis | Cystic Fibrosis;Bronchiectasis | Other: Reaction Time and Postural Control;Other: Muscle oxygenation;Other: Exercise capacity;Other: Balance | Hacettepe University | NULL | Recruiting | 6 Years | 18 Years | All | 60 | Turkey | |
| 3 | NCT02684552 (ClinicalTrials.gov) | February 2016 | 12/2/2016 | Non Invasive Ventilation During Physical Training in Cystic Fibrosis | Physiotherapist in Charge of the Study | Cystic Fibrosis | Device: Non invasive ventilation;Device: Oxygen | Karolinska University Hospital | NULL | Completed | 18 Years | 90 Years | Both | 8 | N/A | Sweden |
| 4 | NCT02262871 (ClinicalTrials.gov) | December 2014 | 7/10/2014 | HFN Versus NIV in Cystic Fibrosis. The HIFEN Study | Randomized Cross-over Physiologic Study of High Flow Nasal Oxygen Cannula Versus Non-invasive Ventilation in Cystic Fibrosis. The HIFEN Study | Cystic Fibrosis | Device: High flow nasal oxygen cannula;Device: Noninvasive ventilation | St. Michael's Hospital, Toronto | NULL | Completed | 18 Years | N/A | All | 15 | N/A | Canada |
| 5 | NCT01586728 (ClinicalTrials.gov) | October 2012 | 18/1/2012 | Oxygen Therapy in Cystic Fibrosis | Indication and Benefits of Nocturnal Oxygen Therapy in Cystic Fibrosis | Cystic Fibrosis | Other: Air - oxygen;Other: Oxygen - Air | Assistance Publique - Hôpitaux de Paris | Vaincre la Mucoviscidose | Terminated | 6 Years | N/A | Both | 8 | N/A | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT01731015 (ClinicalTrials.gov) | January 2012 | 16/11/2012 | Imaging Lung Function Using Oxygen Enhanced MRI | A Pilot Study for Evaluation of Regional Lung Function in Normal Subjects and Subjects With Airway and Lung Disorders Using 1H Magnetic Resonance Imaging With Oxygen as a Contrast Agent | COPD;Asthma;Cystic Fibrosis;Emphysema;Small Airways Disease | Drug: Medical Grade Oxygen | Hal C Charles | NULL | Completed | 18 Years | 90 Years | Both | 15 | Phase 1 | United States |
| 7 | NCT01710449 (ClinicalTrials.gov) | September 2009 | 17/10/2012 | Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen | Evaluation of Regional Ventilation in Normal Subjects and Subjects With Airway and Lung Disorders (COPD, Asthma, Emphysema, Small Airway Disease and Cystic Fibrosis) Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen. | COPD;Asthma;Cystic Fibrosis;Emphysema;Small Airways Diseases | Drug: perfluorinated gas/oxygen mixture | Hal C Charles | NULL | Completed | 18 Years | N/A | Both | 44 | Phase 1 | United States |
| 8 | NCT00157183 (ClinicalTrials.gov) | March 2003 | 9/9/2005 | Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation | Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation | Cystic Fibrosis | Device: Nocturnal oxygen , nocturnal bi-level positive pressure ventilation | Bayside Health | National Health and Medical Research Council, Australia;Monash University;Cystic Fibrosis Australia | Completed | 18 Years | 75 Years | Both | 59 | Phase 1;Phase 2 | Australia |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JMA-IIA00357 | 01/07/2018 | 19/06/2018 | Phase II trial of helium / oxygen mixed gas for respiratory failure secondary to airway obstructive lesion in children | Phase II trial of helium / oxygen mixed gas for respiratory failure secondary to airway obstructive lesion in children | Respiratory failure due to airway obstructive lesion such as acute bronchiolitis, congenital tracheal stenosis, bronchial asthma attack | Intervention type:DRUG. Intervention1:Helium / oxygen mixed gas inhalation therapy, Dose form:INSUFFLATION, Route of administration:INHALATIONAL, intended dose regimen:Helium / oxygen mixed gas . | Tokyo Metropolitan Children's Medical Center | National Center for Child Health and Development | Recruiting | No Limit | <20 YEARS | BOTH | 15 | Phase 2 | Japan |